BAYER AG NA O.N.
Commented by André Will-Laudien on November 25th, 2024 | 07:00 CET
Takeovers – The 200% opportunities for 2025! Speculate now on the turnaround for Evotec, BioNxt, Bayer and Nel ASA!
The DAX 40 index is going from strength to strength, following the huge wave of buying since the US election. High-tech and defense stocks are leading the charge. Contrary to this positive trend, biotech stocks have so far been ignored. However, since interest rates are likely to be lowered for the foreseeable future due to the weakening economy, the time of the research-intensive life sciences industry will soon return. There are takeover rumors about Evotec. BioNxt is currently undervalued, and Bayer should be among the winners next year after successful restructuring efforts. It is worth taking a closer look.
Read
Commented by Juliane Zielonka on November 21st, 2024 | 07:15 CET
Bayer, BioNxt Solutions, BioNTech – Patents and acquisitions for market penetration
Three companies in the pharmaceutical industry are pursuing different strategies to strengthen their market position: Bayer is making targeted investments in the Japanese heart medication market and acquiring the rights to a promising active ingredient for treating heart muscle diseases for up to EUR 560 million. BioNxt Solutions is developing an innovative form of medication delivery for drugs to treat the incurable disease of multiple sclerosis - with an absolute focus on patients. The biotech company is thus securing patent protection in key international markets. BioNTech, in turn, is massively expanding into the Asian oncology market with the USD 800 million acquisition of the Chinese company Biotheus. All three companies are expanding their positions in lucrative future markets. Which strategy will be successful?
Read
Commented by Fabian Lorenz on November 20th, 2024 | 08:15 CET
Takeover battle and soaring profits! Evotec, Bayer, Saturn Oil + Gas
A bombshell announcement came from Evotec late last week. US biotech company Halozyme Therapeutics is offering EUR 11 per Evotec share. Evotec was not informed in advance and seems to be preparing to fend off the takeover. Analysts believe the share price has moved far away from its fundamental value. So, should investors sell the stock now? Experts suggest investors should buy shares of Saturn Oil & Gas. The mid-sized oil producer from Canada is expected to be among the winners under the upcoming Trump administration and will likely soon be paying an attractive dividend. The stock has clear catch-up potential. Meanwhile, analysts are significantly reducing the target price for Bayer. Is there a chance of a turnaround at the agricultural and pharmaceutical giant?
Read
Commented by Armin Schulz on November 20th, 2024 | 07:00 CET
Evotec, Nyxoah, Bayer – A lot of excitement in the healthcare industry
The healthcare sector is currently abuzz with activity. Evotec is the focus of a potential takeover by the US company Halozyme, which has caused the shares of the German biotech company to skyrocket. At the same time, the Belgian medical technology company Nyxoah expects to receive FDA approval soon for its Genio system for the treatment of sleep apnea, which would pave the way for its market entry in the US. Bayer, on the other hand, disappointed with its latest quarterly figures, which showed a significant decline in revenue and EBITDA, leading to a slide in its share price. We take a closer look at these three companies.
Read
Commented by Juliane Zielonka on November 14th, 2024 | 07:45 CET
Daimler Truck, dynaCERT, Bayer AG: Contrasts in Q3: Established companies under pressure, newcomers with breakthroughs
Established DAX corporations such as Bayer AG and Daimler Truck, a Mercedes-Benz Group company, are facing a headwind in the third quarter of 2024. However, the Canadian cleantech specialist dynaCERT is on the verge of its commercial breakthrough. The Leverkusen-based Bayer Group has to revise its forecast downwards. The agriculture business, in particular, is a cause for concern, while the pharmaceuticals division is scoring points with new drugs. At Daimler Truck, strong business in North America is stabilizing the balance sheet, while business in Europe is under pressure. dynaCERT, on the other hand, has received the valuable Verra certification for its hydrogen technology for diesel optimization after twenty years of development work. Investors finally have a viable hydrogen use case for logistics.
Read
Commented by André Will-Laudien on November 13th, 2024 | 07:30 CET
Gold correction - Now is the time to take advantage of the lows! Takeover rumors at Evotec, Desert Gold, Bayer and SMCI
The re-election of Donald Trump as US President had varying effects on the capital markets. The US dollar gained against all currencies, while the hot topic Bitcoin reached new all-time highs of over USD 90,000. The enormous influx of funds into the US stock markets initially slowed down other exchanges. At the same time, the previously sought-after precious metals corrected sharply, putting pressure on mining stocks again. The first shockwaves have now been absorbed, and attention is turning to the real political issues that the White House will now push forward. Defense, industry, and security are in the spotlight, while biotech and green tech remain sidelined. There are some interesting special movements that we will examine here.
Read
Commented by Armin Schulz on November 12th, 2024 | 07:00 CET
Bayer, BioNxt Solutions, Novo Nordisk – Opportunities in the healthcare industry
In a market characterized by technological breakthroughs and the growing demand for innovative therapies, companies such as Bayer, BioNxt Solutions and Novo Nordisk offer exciting investment opportunities. While Bayer, a global pharmaceutical giant with a broad product portfolio, promises stability and long-term growth, BioNxt Solutions relies on highly specialized biotechnological innovations with disruptive potential. Novo Nordisk, a leading player in diabetes and metabolic disorders, is benefiting from the growing demand for solutions for chronic diseases. For investors looking to capitalize on trends in the healthcare industry, these three companies could make all the difference.
Read
Commented by Juliane Zielonka on November 7th, 2024 | 07:00 CET
Vidac Pharma, BioNTech, Bayer - Billion-Dollar Gene Therapy Market Attracts Investors
Two trends are emerging in the pharmaceutical industry: personalized medicine, which tailors therapies to the genetic profile of individual patients, and the development of highly specific active ingredients that target biological mechanisms. Vidac Pharma is one of the companies focusing on these targeted therapies and recently received a groundbreaking US patent for its innovative approach to normalizing cancer cell metabolism - a concept known as the "Warburg effect reversal." BioNTech is driving its transformation from COVID-19 vaccine producer to cancer specialist, with promising Phase II trials underway for treatments targeting lung and breast cancers. Bayer, meanwhile, is under pressure due to disappointing sales of its partner Regeneron's eye drug Eylea® – the second most important product in the portfolio, which has to hold its own against growing competition. Where is an investment worthwhile?
Read
Commented by André Will-Laudien on November 6th, 2024 | 08:00 CET
US election and the biotech sector – A hot November is on the cards! BioNTech, Pfizer, Nyxoah, Bayer or Evotec?
With anticipation building for both the Q3 earnings season and the US election results, the markets are in a wait-and-see mode. Democrat frontrunner Kamala Harris is said to be committed to continuing the successful policies of her predecessor Joe Biden. Of course, science, research and climate protection are in the spotlight. Her rival, Donald Trump, is said to be more concerned with strengthening the traditional economy, where automotive engineering, the defense industry and security companies come to the fore. Additionally, markets are looking to central banks for cues, as lower interest rates would be a boon for the biotech sector. Here are some investment ideas for dynamic investors in this promising climate.
Read
Commented by Juliane Zielonka on October 30th, 2024 | 07:45 CET
Nyxoah, Bayer and Palantir - The billion-dollar precision medicine market: Why investors are now taking notice
Precision medicine is revolutionizing global healthcare: Experts predict that this future market will reach over USD 175 billion by 2028, driven by the growing demand for individualized treatment methods. Three companies stand out in particular: Belgian medical technology company Nyxoah is developing a mask-free therapy for the 936 million people worldwide with sleep apnea with its Genio system, while Bayer AG is revolutionizing fertility treatment through real-time hormone monitoring through its partnership with Impli. With its foundry platform, technology leader Palantir enables pharmaceutical giant Sanofi to analyze the health data of over 300 million patients. These patient-centered innovations not only promise better treatment outcomes for millions of people but also present investors access to one of the most dynamic growth markets in the healthcare sector.
Read